Rib-X Pharmaceuticals, Inc. to Present at the Thomas Weisel Partners Healthcare Conference
New Haven, Connecticut. August 27, 2008 — Rib-X Pharmaceuticals, Inc.,
a development stage company focused on the discovery and development of novel antibiotics for
the treatment of antibiotic resistant infections, announced today that Susan Froshauer, Ph.D.,
President and Chief Executive Officer, is scheduled to present at the Thomas Weisel Partners
Healthcare Conference on September 4, 2008, at 9:45 A.M. The conference will be held from
September 3—5, 2008 at the Four Seasons, Boston, Massachusetts.
About Rib-X Pharmaceuticals
Rib-X Pharmaceuticals, Inc. is a product driven small molecule drug discovery and development company focused on the structure based design of new classes of antibiotics. The Company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in the fundamental process of protein synthesis. Many known, commercially valuable antibiotics bind to the ribosome, including those used to treat both community acquired and hospital acquired pathogens. The Company's integrated research strategy, which combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology, and biochemistry, allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinctive new antibiotic classes. The Company currently has two programs in human clinical trials, the radezolid (RX-1741) designer oxazolidinone program as an oral/IV agent to treat serious hospital Gram-positive infections and the delafloxacin, (RX-3341) program, a next generation fluoroquinolone, active against a broad spectrum of bacteria, including methicillin resistant Staphylococcus aureus. Additionally, the Company has multiple drug discovery programs. The first of these is an exciting discovery program that is well on its way toward the identification of new chemical classes of antibiotics active against multi-drug resistant Gram-negative bacteria in the hospital. The second of these programs is focused on design and development of an IV and orally active macrolide for treatment of infections in the nursing home and hospital setting, including those caused by MRSA and enterococci. Radezolid and the multiple discovery programs derive from Rib-X's proprietary use of the ribosome structure and computational tools.
About Rib-X Pharmaceuticals
Rib-X Pharmaceuticals, Inc. is a product driven small molecule drug discovery and development company focused on the structure based design of new classes of antibiotics. The Company's underlying drug discovery engine capitalizes on its proprietary high-resolution crystal structure of the ribosome, which performs an essential role in the fundamental process of protein synthesis. Many known, commercially valuable antibiotics bind to the ribosome, including those used to treat both community acquired and hospital acquired pathogens. The Company's integrated research strategy, which combines state-of-the-art, proprietary computational analysis, X-ray crystallography, medicinal chemistry, microbiology, and biochemistry, allows it to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms. Rib-X's iterative intelligent engine has yielded several distinctive new antibiotic classes. The Company currently has two programs in human clinical trials, the radezolid (RX-1741) designer oxazolidinone program as an oral/IV agent to treat serious hospital Gram-positive infections and the delafloxacin, (RX-3341) program, a next generation fluoroquinolone, active against a broad spectrum of bacteria, including methicillin resistant Staphylococcus aureus. Additionally, the Company has multiple drug discovery programs. The first of these is an exciting discovery program that is well on its way toward the identification of new chemical classes of antibiotics active against multi-drug resistant Gram-negative bacteria in the hospital. The second of these programs is focused on design and development of an IV and orally active macrolide for treatment of infections in the nursing home and hospital setting, including those caused by MRSA and enterococci. Radezolid and the multiple discovery programs derive from Rib-X's proprietary use of the ribosome structure and computational tools.
| Media/Investor Contact Information |
|---|
|
Gina Nugent
The Yates Network 617.460.3579 gina@theyatesnetwork.com |